AbCellera Biologics

ABCL

Market cap $1.12B

AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Analyst Great.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.

AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sachs Group, Inc., Research Division Joshua Nickerson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Jacqueline Kisa - TD Cowen, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call.

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.

AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent revenue and net income declines due to the business model shift, ABCL is well-funded and expects revenue to double in 2026 as clinical batches commence.

Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.

Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.